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Welcome to this special issue of the Journal of Diabetes
research that is focussed on diabetic neuropathy (DN) and
features a wide range of articles covering accepted topics
related to the epidemiology, pathogenesis, and treatment of
diﬀerent aspects of DN. Diabetic peripheral neuropathy
(DPN) and diabetic autonomic neuropathy (DAN) are the
most common diabetes-related microvascular complications
and can result in signiﬁcant increase in morbidity, such as
chronic pain, foot ulcerations and amputations, and mortal-
ity. But despite these signiﬁcant consequences, current
eﬀective screening and treatment strategies are lacking unlike
other diabetes-related microvascular complications such as
retinopathy and nephropathy. This usually results in delay
in the diagnosis of DN till it is well established and more
diﬃcult to treat while retinopathy and nephropathy can be
detected early using current screening strategies such as
retinal images and urinary assessments which allow early
interventions to prevent the progression of the disease.
Glucose control is still the only main disease-modifying
therapy for diabetic neuropathy, and several disease modiﬁ-
cation clinical trials for diabetic neuropathy have failed due
to lack of sensitive biomarker. There exists an urgent need
to identify the most accurate early biomarker of nerve dam-
age to better diagnose DPN in the clinical care of patients
and, in particular, to permit an accurate evaluation of future
therapies in clinical trials.
This special issue aimed to provide a platform for
advance in basic and clinical science in the ﬁeld of DN.
In an elegant and well-constructed review, L. M. Román-
Pintos et al. summarised the literature regarding the
epidemiology, risk factors, pathophysiology, diagnosis,
and treatments of DN. The review provides important
insights into the mechanisms underlying the pathogenesis
of DN particularly in relation to oxidative stress, inﬂam-
mation, and mitochondrial dysfunction providing the
experimental basis for each mechanism followed by its
translational ﬁndings in patients.
N. A. Gavan et al. reported the outcome of the most
recent epidemiological study performed in Romania. The
study revealed a high prevalence of undisclosed DN, as well
as a high prevalence of foot ulcers and amputations in the
study population.
A paper by A. A. Tahrani et al. showed ethnic diﬀerences
in microvascular function in the lower limbs in the South
Asian patients with type 2 diabetes compared to White Euro-
peans. In this interesting study, skin microvascular blood
ﬂow assessment demonstrated reduced heating ﬂux but pre-
served acetylcholine response in South Asians. This might be
related to the lower prevalence of DPN in South Asians [1].
Patients with diabetes have been reported to have a
greater decline in cognitive function and a higher risk of
developing dementia. In an interesting study, C.-W. Chang
et al. showed in their large study population from Taiwan
that regular uptake dosage of aspirin might decrease the
risk of developing Alzheimer’s disease in patients with
type 2 diabetes.
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M. C. Perez-Matos et al. reviewed the evidences about
lipid-modifying therapies in DPN. The authors concluded
that the future research should concentrate on targeting
lipids with one or more aggressive interventions speciﬁcally
in patients whose DPN is detectable but whose progression
can still be largely prevented [2].
A. Ando et al. investigated the relationship between
macroangiography and DPN applying cardio-ankle vascular
index (CAVI) in patients with type 2 diabetes. Their study
showed that the CAVI, arterial stiﬀness, and vascular damage
marker have a close relationship with DPN [3].
F. Ishibashi et al. investigated whether the pupillary light
reﬂex (PLR) mediated by intrinsically photosensitive retinal
ganglion cells is impaired in type 2 diabetic patients without
clinical evidences of autonomic neuropathy. The results
showed that blue light induced a more intense and rapid
PLR in control subjects and diabetic patients than did red
light, and the PLR stimulated by blue light in patients with
type 2 diabetes without DAN was more severely impaired
than that caused by red light [4].
V. L. Newton et al. demonstrated the increased numbers
of neutrophils and levels of L-selectin which is an adhesion
molecule important for neutrophil transmigration, in the
lumbar spinal cord after 8 weeks of STZ-induced diabetic
rats. These ﬁndings suggest that dysregulated spinal L-
selectin and neutrophil inﬁltration into the spinal cord could
contribute to the pathogenesis of painful DPN [5].
The review by T. Kucera et al. summarised the current
view on the etiology, diagnostics, and treatment of Charcot
neuropathic osteoarthrophy in diabetes, with particular
focus on preserving the extremity through surgical
intervention.
Callus formation has long been an important factor to
be considered as a predictor for ulceration and subsequent
amputation. However, the role of vertical stress (pressure)
and shear stress associated with callus has yet to be clari-
ﬁed. A. Amemiya et al. from the Department of Wound
Care, Tokyo, Japan, looked into the role of hyperkeratosis
(callus) and its link to frictional shear forces and subse-
quent tissue loss.
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